Taiwan
· Delayed Price · Currency is TWD BioGend Therapeutics Statistics
Total Valuation
TPEX:6733 has a market cap or net worth of TWD 3.48 billion. The enterprise value is 2.93 billion.
| Market Cap | 3.48B |
| Enterprise Value | 2.93B |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6733 has 124.26 million shares outstanding. The number of shares has increased by 0.27% in one year.
| Current Share Class | 124.26M |
| Shares Outstanding | 124.26M |
| Shares Change (YoY) | +0.27% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 4.11% |
| Owned by Institutions (%) | 2.56% |
| Float | 74.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.38 |
| PB Ratio | 4.28 |
| P/TBV Ratio | 5.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.10 |
| EV / Sales | 16.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.49 |
Financial Position
The company has a current ratio of 25.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.12 |
| Quick Ratio | 23.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -732.87 |
Financial Efficiency
Return on equity (ROE) is -16.02% and return on invested capital (ROIC) is -10.13%.
| Return on Equity (ROE) | -16.02% |
| Return on Assets (ROA) | -9.58% |
| Return on Invested Capital (ROIC) | -10.13% |
| Return on Capital Employed (ROCE) | -17.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.19 |
| Inventory Turnover | 2.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.23% in the last 52 weeks. The beta is 0.47, so TPEX:6733's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -25.23% |
| 50-Day Moving Average | 29.57 |
| 200-Day Moving Average | 34.14 |
| Relative Strength Index (RSI) | 47.09 |
| Average Volume (20 Days) | 83,199 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6733 had revenue of TWD 179.57 million and -138.80 million in losses. Loss per share was -1.13.
| Revenue | 179.57M |
| Gross Profit | 137.68M |
| Operating Income | -144.38M |
| Pretax Income | -149.28M |
| Net Income | -138.80M |
| EBITDA | -97.01M |
| EBIT | -144.38M |
| Loss Per Share | -1.13 |
Balance Sheet
The company has 585.36 million in cash and 8.52 million in debt, giving a net cash position of 576.83 million or 4.64 per share.
| Cash & Cash Equivalents | 585.36M |
| Total Debt | 8.52M |
| Net Cash | 576.83M |
| Net Cash Per Share | 4.64 |
| Equity (Book Value) | 812.65M |
| Book Value Per Share | 6.38 |
| Working Capital | 659.66M |
Cash Flow
In the last 12 months, operating cash flow was -95.50 million and capital expenditures -560,000, giving a free cash flow of -96.06 million.
| Operating Cash Flow | -95.50M |
| Capital Expenditures | -560,000 |
| Free Cash Flow | -96.06M |
| FCF Per Share | -0.77 |
Margins
Gross margin is 76.67%, with operating and profit margins of -80.40% and -77.29%.
| Gross Margin | 76.67% |
| Operating Margin | -80.40% |
| Pretax Margin | -83.14% |
| Profit Margin | -77.29% |
| EBITDA Margin | -54.02% |
| EBIT Margin | -80.40% |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6733 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.27% |
| Shareholder Yield | -0.27% |
| Earnings Yield | -3.99% |
| FCF Yield | -2.76% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |